Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients

Abstract

Introduction

To investigate the potential prognostic value of image analysis of pelvic bone metastasis in newly diagnosed prostate cancer patients.

Methods

Data from 69 patients with both bone scintigraphy and pelvic CT images were selected for this analysis. Open source software (3D Slicer version 4.8.1.) was used for image analysis. Metastatic pelvic bone lesions were manually contoured, and radiomic features were extracted. As risk factors for overall survival (OS) and cause-specific survival (CSS), 105 radiomic features and clinical risk factors including age, initial prostate-specific antigen, Gleason score, TNM stage, lactate dehydrogenase (LDH), hemoglobin (Hb), alkaline phosphatase, extent of disease, visceral metastases, and radiotherapy were assessed by uni- and multivariate analyses.

Results

Median follow-up was 41 months (range 0–157 months). Five-year overall survival and cause-specific survival rate were 37.9% and 43.5%, respectively. After multivariate analysis, LDH, Hb, and “maximum 2D diameter” defined as maximum tumor size in the axial plane were detected as risk factors for OS. Gleason sum, LDH, and maximum 2D diameter were detected as risk factors for CSS.

Conclusion

Maximum 2D diameter was detected as a significant prognostic factor for metastatic prostate cancer patients.

This is a preview of subscription content, log in to check access.

Fig. 1

Availability of data and materials

The datasets generated and/or analyzed during the current study are not publicly available.

Abbreviations

OS:

Overall survival

CSS:

Cause-specific survival

LDH:

Lactate dehydrogenase

Hb:

Hemoglobin

EOD:

Extent of disease

ALP:

Alkaline phosphatase

References

  1. 1.

    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281(17):1591–7.

    CAS  Article  Google Scholar 

  2. 2.

    Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018;392:2353–66.

    Article  Google Scholar 

  3. 3.

    Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.

    CAS  Article  Google Scholar 

  4. 4.

    Gandaglia G, Karakiewicz PI, Briganti A, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68(2):325–34.

    Article  Google Scholar 

  5. 5.

    Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T, Yonese J. Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017;31(7):521–8.

    Article  Google Scholar 

  6. 6.

    Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195–202.

    CAS  Article  Google Scholar 

  7. 7.

    Batson OV. The function of the vertebral veins and their role in the spread of metastases. Ann Surg. 1940;112(1):138–49.

    CAS  Article  Google Scholar 

  8. 8.

    Hess KR, Varadhachary GR, Taylor SH, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Contributions

TH and HI drafted the manuscript. TH, KT, HT, SK, TK, MH, YW, and HI participated in the design of the study. TH and HI performed the statistical analysis. MI and TH supervised the study. TH, KT, HT, SK, TK, MH, YW, and HI collected medical information about this study.

Corresponding author

Correspondence to Hiromichi Ishiyama.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval and consent to participate

This study was approved by the institutional review board of Kitasato University School of Medicine (B17-245). No consent was required as this study used anonymized registry data.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hayakawa, T., Tabata, K., Tsumura, H. et al. Size of pelvic bone metastasis as a significant prognostic factor for metastatic prostate cancer patients. Jpn J Radiol (2020). https://doi.org/10.1007/s11604-020-01004-5

Download citation

Keywords

  • Prostate cancer
  • Radiomics
  • Bone metastasis
  • Computed tomography
  • Pelvis